Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on advanced cancer treatments, has announced its participation in two major healthcare conferences in San Francisco.
CEO Thijs Spoor will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, from 3:45 p.m. to 4:25 p.m. PT at The Westin St. Francis Hotel's Elizabethan B room. Additionally, the company will present at the Biotech Showcase conference on Tuesday, January 14, 2025, at 1:30 p.m. PT, taking place at the Hilton San Francisco - Union Square's Yosemite A Ballroom.
The management team will be available for one-on-one meetings with investors and strategic partners at both conferences, with interested parties directed to contact events@perspectivetherapeutics.com for scheduling.
Perspective Therapeutics (NYSE AMERICAN: CATX), un'azienda di radiobiologici che si concentra su trattamenti avanzati per il cancro, ha annunciato la sua partecipazione a due importanti conferenze sanitarie a San Francisco.
Il CEO Thijs Spoor presenterà al 43° Annual J.P. Morgan Healthcare Conference mercoledì 15 gennaio 2025, dalle 15:45 alle 16:25 PT nella sala Elizabethan B del The Westin St. Francis Hotel. Inoltre, l'azienda presenterà alla conferenza Biotech Showcase martedì 14 gennaio 2025, alle 13:30 PT, che si svolgerà nel ballroom Yosemite A del Hilton San Francisco - Union Square.
Il team dirigente sarà disponibile per incontri individuali con investitori e partner strategici in entrambe le conferenze; le parti interessate possono contattare events@perspectivetherapeutics.com per programmare un incontro.
Perspective Therapeutics (NYSE AMERICAN: CATX), una compañía de radiofármacos centrada en tratamientos avanzados contra el cáncer, ha anunciado su participación en dos importantes conferencias de salud en San Francisco.
El CEO Thijs Spoor presentará en la 43ª Conferencia Anual de Salud de J.P. Morgan el miércoles 15 de enero de 2025, de 3:45 p.m. a 4:25 p.m. PT en la sala Elizabethan B del The Westin St. Francis Hotel. Además, la compañía presentará en la conferencia Biotech Showcase el martes 14 de enero de 2025, a la 1:30 p.m. PT, que tendrá lugar en el Ballroom Yosemite A del Hilton San Francisco - Union Square.
El equipo de gestión estará disponible para reuniones uno a uno con inversores y socios estratégicos en ambas conferencias; las partes interesadas pueden contactar a events@perspectivetherapeutics.com para gestionar la programación.
퍼스펙티브 테라퓨틱스 (NYSE AMERICAN: CATX), 첨단 암 치료에 집중하는 방사선 의약품 회사가 샌프란시스코에서 두 가지 주요 의료 회의에 참여한다고 발표했습니다.
CEO Thijs Spoor는 2025년 1월 15일 수요일 오후 3시 45분부터 4시 25분(PT)까지 The Westin St. Francis 호텔의 Elizabethan B 룸에서 제43회 연례 J.P. Morgan 헬스케어 컨퍼런스에서 발표할 예정입니다. 또한, 회사는 2025년 1월 14일 화요일 오후 1시 30분(PT)에 힐튼 샌프란시스코 - 유니온 스퀘어의 Yosemite A 볼룸에서 열리는 생명공학 쇼케이스 회의에서도 발표할 예정입니다.
경영진 팀은 두 회의에서 투자자 및 전략적 파트너와의 일대일 미팅을 위해 자리를 가질 것이며, 관심 있는 분들은 events@perspectivetherapeutics.com으로 일정 조정을 문의할 수 있습니다.
Perspective Therapeutics (NYSE AMERICAN: CATX), une entreprise de radiopharmaceutiques axée sur les traitements avancés du cancer, a annoncé sa participation à deux grandes conférences de santé à San Francisco.
Le PDG Thijs Spoor présentera lors de la 43e Conférence Annuelle de J.P. Morgan sur la Santé le mercredi 15 janvier 2025, de 15h45 à 16h25 PT dans la salle Elizabethan B de l'hôtel The Westin St. Francis. De plus, l'entreprise présentera à la conférence Biotech Showcase le mardi 14 janvier 2025, à 13h30 PT, qui se tiendra dans la salle Yosemite A du Hilton San Francisco - Union Square.
L'équipe de direction sera disponible pour des réunions individuelles avec des investisseurs et des partenaires stratégiques lors des deux conférences ; les parties intéressées sont priées de contacter events@perspectivetherapeutics.com pour la prise de rendez-vous.
Perspective Therapeutics (NYSE AMERICAN: CATX), ein Unternehmen für Radiopharmazeutika, das sich auf fortschrittliche Krebstherapien konzentriert, hat seine Teilnahme an zwei wichtigen Gesundheitskonferenzen in San Francisco angekündigt.
CEO Thijs Spoor wird am Mittwoch, den 15. Januar 2025, von 15:45 bis 16:25 PT auf der 43. jährlichen J.P. Morgan Healthcare Conference im Elizabethan B Raum des The Westin St. Francis Hotels präsentieren. Darüber hinaus wird das Unternehmen am Dienstag, den 14. Januar 2025, um 13:30 PT auf der Biotech Showcase Konferenz im Yosemite A Ballroom des Hilton San Francisco - Union Square präsentieren.
Das Management-Team wird auf beiden Konferenzen für Einzelgespräche mit Investoren und strategischen Partnern zur Verfügung stehen; interessierte Parteien können sich unter events@perspectivetherapeutics.com zur Terminvereinbarung melden.
- None.
- None.
SEATTLE, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 43nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 15, 2025, at 3:45 p.m. PT. Management will also participate and present at the Biotech Showcase conference alongside the J.P. Morgan Healthcare Conference in San Francisco.
43rd Annual J.P. Morgan Healthcare Conference – Company Presentation
Date: Wednesday, January 15, 2025
Time: 3:45 p.m. - 4:25 p.m. PT
Location: The Westin St. Francis Hotel, San Francisco, CA (Elizabethan B)
Biotech Showcase – Company Presentation
Date: Tuesday, January 14, 2025
Time: 1:30 p.m. PT
Location: Hilton San Francisco - Union Square, Yosemite A (Ballroom Level)
Mr. Spoor and the Perspective management team will be available for one-on-one meetings with investors and strategic partners at each of these conferences. Please contact events@perspectivetherapeutics.com for scheduling.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moeities. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moeities which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatment applications for cancers throughout the body; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moeities; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moeities provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to develop a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com
Russo Partners, LLC
Nic Johnson
FAQ
When and where will Perspective Therapeutics (CATX) present at the J.P. Morgan Healthcare Conference 2025?
What conferences will Perspective Therapeutics (CATX) attend in January 2025?
How can investors schedule meetings with CATX management at the 2025 healthcare conferences?